SEVERE LOSS-OF-FUNCTION SCN5A MUTATIONS ASSOCIATED WITH SINUS NODE DYSFUNCTION, ATRIAL ARRHYTHMIAS, AND POOR PACEMAKER CAPTURE  by Chiang, David et al.
Congenital Heart Disease
A533
JACC March 17, 2015
Volume 65, Issue 10S
severe loss-of-funCtion sCn5a mutations assoCiated with sinus node dysfunCtion, 
atrial arrhythmias, and poor paCemaker Capture
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: Contemporary Issues in Pediatric Arrhythmia
Abstract Category: 11.  Congenital Heart Disease: Pediatric
Presentation Number: 1152-329
Authors: David Chiang, Jeffrey Kim, Santiago Valdes, Caridad De La Uz, Yuxin Fan, Christina Miyake, Baylor College of Medicine, 
Houston, TX, USA, Texas Children’s Hospital, Houston, TX, USA
Background:  Mutations in the SCN5A gene, which encodes the NaV1.5 channel, have been implicated in inheritable cardiac diseases, 
primarily long QT and Brugada syndromes. We now report an association between severe SCN5A mutations, sinus node dysfunction, atrial 
arrhythmias and poor pacemaker capture.
methods:  A retrospective chart review of all SCN5A mutations at a single center was conducted. Patients with a diagnosis of Brugada or 
long QT syndrome were excluded.
results:  There were a total of 23 patients with SCN5A mutations, 15 of whom had a definitive diagnosis of Brugada or long QT syndrome. 
Of the remaining 8 patients, 7 were diagnosed with sinus node dysfunction, atrial arrhythmias, and poor pacemaker capture either in 
the atria, ventricles or both. In all 7 patients, inability to capture myocardium or excessive capture thresholds was found at pacemaker 
implant. Capture thresholds have remained elevated in all; however some patients have demonstrated a waxing and waning course with 
intermittent complete loss of capture resulting in syncope. Genetic testing revealed 6 distinct SCN5A mutations, one of which has never 
been previously reported. Bioinformatic analysis and literature review demonstrated: 1) a frame-shift mutation leading to an early stop 
codon and protein truncation, 2) a splice site mutation resulting in inclusion of an intron which then lead to early stop codon and protein 
truncation, 3) missense mutation resulting in a protein trafficking defect, and 4) missense mutations that may affect either NaV1.5 activation 
or inactivation or both. Together, all of these 6 SCN5A mutations are predicted to result in severely compromised or complete ablation of 
NaV1.5 function, albeit via distinct molecular mechanisms.
Conclusion:  This is the first series of poor pacemaker capture associated with SCN5A mutations. Significant decreases in NaV1.5 
function appear to be involved in fluctuating capture thresholds and intermittent complete loss of pacemaker capture. Recognition of this 
association in a subset of patients with SCN5A mutations will be important for future management.
